Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34145248.
- Also identified by DOI 10.1038/s41467-021-23957-5 and PMC identifier 8213728.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Claudin-low breast cancer represents an aggressive molecular subtype that is comprised of mostly triple-negative mammary tumor cells that possess stem cell-like and mesenchymal features. Little is known about the cellular origin and oncogenic drivers that promote claudin-low breast cancer. In this study, we show that persistent oncogenic RAS signaling causes highly metastatic triple-negative mammary tumors in mice. More importantly, the activation of endogenous mutant KRAS and expression of exogenous KRAS specifically in luminal epithelial cells in a continuous and differentiation stage-independent manner induces preneoplastic lesions that evolve into basal-like and claudin-low mammary cancers. Further investigations demonstrate that the continuous signaling of oncogenic RAS, as well as regulators of EMT, play a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.
Medical subject headings
- Claudins
- Mammary Glands, Animal
- Mammary Neoplasms, Animal
- Mesenchymal Stem Cells
- Proto-Oncogene Proteins p21(ras)